Critical Reviews in Oncology/Hematology 39 (2001) 139 – 146
In vitro and preclinical targeted alpha therapy for melanoma,
breast, prostate and colorectal cancers
B.J. Allen
a,c
*, S. Rizvi
a,c
, Y. Li
a
, Z. Tian
b
, M. Ranson
b
a
Centre for Experimental Radiation Oncology, St George Cancer Care Centre, Gray Street, Kogarah NSW 2219, Australia
b
Centre for Experimental Radiation Oncology, Biology, Uniersity of Wollongong, NSW, Australia
c
Centre for Experimental Radiation Oncology, Uniersity of NSW, Australia
Accepted 12 January 2001
Contents
1. Introduction ............................................... 140
1.1. Targeting cancer cells ....................................... 140
1.1.1. Monoclonal antibodies (mab) ............................... 140
1.1.2. Plasminogen activation inhibitor (PAI-2) ........................ 141
1.2. Targeted alpha therapy ...................................... 141
1.2.1. Biological effect ....................................... 141
1.2.2. Requirements for control of metastases ......................... 141
2. Methods .................................................. 141
2.1. Radioisotopes ............................................ 141
2.2. Chelators............................................... 141
2.3. Cell lines ............................................... 142
2.4. Cell survival assay ......................................... 142
2.5. In vivo model ............................................ 142
2.5.1. Immunohistochemistry ................................... 142
3. Results................................................... 142
3.1. Radioisotope production and labeling .............................. 142
3.2. In Vitro studies ........................................... 142
3.2.1. Melanoma .......................................... 142
3.2.2. CRC ............................................. 142
3.2.3. Prostate cancer ....................................... 143
3.3. In vivo studies ........................................... 143
3.3.1. Melanoma .......................................... 143
3.3.2. Breast cancer ........................................ 144
3.3.3. Toxicology .......................................... 144
4. Conclusions ................................................ 144
Acknowledgements ............................................. 145
References .................................................. 145
Biography................................................... 146
www.elsevier.com/locate/critrevonc
* Corresponding author. Tel.: +61-2-93503855; fax: +61-2-93502456.
E-mail address: b.allen@unsw.edu.au (B.J. Allen).
1040-8428/01/$ - see front matter © 2001 Elsevier Science Ireland Ltd. All rights reserved.
PII:S1040-8428(01)00113-5